Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRT6008 Plus Chemotherapy in Unresectable Locally Advanced Pancreatic Carcinoma
NCT07555587Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NRT6008 in pancreatic carcinoma. Primary endpoint: Adverse Events and Severe Adverse Events at 18 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
NRT6008
03
Conditions
pancreatic carcinoma
Beyond the preview
Go deeper on NCT07555587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07555587.